Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Public ClinicalTrials.gov record NCT03079687. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multiple Patient Expanded Access Program for Olaparib Tablets for the Maintenance Treatment Following Response (Complete Response or Partial Response) to Platinum-based Chemotherapy in Patients With Platinum-sensitive Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Study identification
- NCT ID
- NCT03079687
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Olaparib tablets Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Oct 24, 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Duarte | California | 91010 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Roseville | California | 95661 | — |
| Research Site | Gainesville | Florida | 32608 | — |
| Research Site | Scarborough | Maine | 04074 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Columbia | Missouri | 65212 | — |
| Research Site | Albuquerque | New Mexico | 87106 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Winston-Salem | North Carolina | 27157-1023 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03079687, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03079687 live on ClinicalTrials.gov.